More than a hundred thousand women diagnosed with breast cancer in Europe and the US each year could avoid chemotherapy by taking a gene test made by Agendia, a Dutch biotech group, which can attempt to predict whether the disease is likely to return.
Women with early-stage breast cancer are often given chemotherapy after surgery if their tumours are over a certain size or have started to spread to the lymph nodes, factors which suggest they have a high clinical risk of suffering a recurrence.
But many of them are believed to gain little benefit from undergoing the punishing therapy.
您已閱讀28%（588字），剩餘72%（1537字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。